miR-185 and miR-342 control lipogenesis and cholesterol synthesis in prostate cancer cells by inhibiting SREBP1 and SREBP2 expression and downregulating their target genes FASN and HMGCR. Upregulation of miR-185 and -342 induces caspase-dependent apoptosis in prostate cancer cells and regression of prostate tumors (Li et al., 2013). Here, FASN is linked to prostate carcinoma.